In summation, we have demonstrated that systemically bioavailable butyrate dosed through SerBut is able to modulate immunity, thus suppressing atherosclerosis progression and liver pathology in the ApoE–/– HFD murine model of atherosclerosis. Here, APOE is linked to atherosclerosis.